enzalutamide

4-(6-chloro-1-oxo-3-thioxo-9,9a-dihydro-1H-imidazo[1,5-a]indol-2(3H)-yl)-2-(trifluoromethyl)-benzonitrile Drug Name： Enzalutamide Research Code： MDV-3100 Trade Name： Xtandi® MOA： Androgen receptor inhibitor Indication： Prostate cancer Status： Approved Company： Medivation (Originator) , Astellas Sales： $2,100.8 Million (Y2015); $1,247.3 Million (Y2014); $546 Million (Y2013); $148.8 Million (Y2012); ATC Code： L01 Approved Countries or AreaUpdate Date：2015-07-29 US EU JP Approval Date Approval Type Trade Name …

Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer

4-(6-chloro-1-oxo-3-thioxo-9,9a-dihydro-1H-imidazo[1,5-a]indol-2(3H)-yl)-2-(trifluoromethyl)-benzonitrile WILL BE UPDATED……… Prostate cancer, one of the most malignant tumors worldwide, is the second leading cause of cancer deaths among men in America . Although androgen deprivation therapy (ADT) has been proved to be effective initially, the tumor will eventually progress and develop into the lethal castration resistant prostate cancer (CRPC) . The …